• Friday, September 7, 2018 @ 10:45 am

Creoptix AG, a Switzerland-based company focused on next generation bioanalytical instruments, announced it secured new investment in the company from Waters Corporation (NYSE: WAT).  Additionally, Geoff Gerhardt, Ph.D., Sr. Director, Corporate Development at Waters will join Creoptix board of directors effective immediately.

Creoptix developed and markets Creoptix WAVE systems to study molecular interactions in real-time. Based on proprietary waveguide technology and no-clog microfluidics, WAVE systems uniquely combine unparalleled resolution and crude sample robustness to generate unmatched data quality.   The technology is facilitating new analytical applications that were not previously possible, such as membrane protein analysis in drug discovery and real-time kinetic interaction studies in body fluids for biomarker and biotherapeutics development.

“We are very proud to be partnering with Waters Corporation as corporate investor, including participation on our board of directors,” said Matyas Vegh, CEO of Creoptix. “This not only bolsters our analytical science expertise and resources to expand our presence in the market, but it also acknowledges our technology and its potential.”

” New innovative analytical technologies are critical to accelerating biopharmaceutical therapeutic drug development processes. Creoptix has developed unique technology that enables protein researchers to generate higher quality protein binding data with significantly improved robustness compared to legacy technologies.  Waters is excited to support Creoptix's vision for widespread adoption of its WAVE System technology,” said Dr. Gerhardt.

You may also be interested in